PHK
ELEV

Point72 Hong Kong’s Elevation Oncology ELEV Stock Holding History

Point72 Hong Kong’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,649
Closed -$131K – 2100
2021
Q2 		$131K Buy
+9,649
New +$119K ﹤0.01% 1254

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Point72 Hong Kong's ELEV Position: Q3 2021 in Review

Point72 Hong Kong sold out of Elevation Oncology (ELEV) in Q3 2021, closing a stake of 9,649 shares — an estimated $131K sold.

Point72 Hong Kong first reported a position in ELEV in Q2 2021 and held it in 1 quarter. The position peaked at $131K in Q2 2021. 22 funds tracked by Wall St. Rank hold ELEV as of Q3 2021.

  • Point72 Hong Kong reported no remaining Elevation Oncology position as of Q3 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 9,649 Elevation Oncology shares in Q3 2021, an estimated $131K.
  • Point72 Hong Kong first reported a position in Elevation Oncology in Q2 2021 and held it in 1 quarter.
  • Point72 Hong Kong's Elevation Oncology position peaked at $131K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2021.

Based on Point72 Hong Kong's 13F filing for Q3 2021, filed 15 Nov 2021.